On April 11, 2025, Titan Pharmaceuticals announced it completed a $1 million Private Placement by issuing 100,000 shares of Series B Convertible Preferred Stock, which it believes restores its stockholders equity to at least $2.5 million, complying with Nasdaq's listing requirements after being notified on March 26, 2025, about non-compliance.